U.S. FDA Approves Labeling Update of REXULTI® (brexpiprazole) For Maintenance Treatment of Schizophrenia
Sunovion to Present Data on Latuda® (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress
FDA will require stronger warnings for certain opioid medications
FDA Heightens Warning About Drug Combinations
Some readers favor the flexibility of a sprawling portfolio, while others prefer a simpler approach.
When Bill Buechler slipped into a coma , little did he know he'd emerge from his experience with the best firm ever.
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...
Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.